NCT07922798
A Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of UBT48128 Tablets in Healthy Participants
StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Study completion pushed from Dec 30, 2026 to Mar 31, 2027
- Start date: Nov 29, 2026 to Dec 1, 2026
- Secondary endpoints: details revised at 1 of 9 entries
- Study title shortened, about 3 words
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
incidence of adverse events (AEs), adverse drug reactions (ADRs), serious adverse events (SAEs), etc,..
Timeframe: Baseline to Day 6 and Day 13
Secondary (9)
Cmax
Tmax
AUC0-t
AUC0-∞
λz
Show 4 moreShow less
t1/2
CL/F
Vz/F
MRT
Arms and interventions
UBT48128Experimental
Ascending single doses - 6 dose levels
PlaceboPlacebo comparator
Ascending single doses - 6 dose levels
Drugs: UBT48128, Placebo
Sites
1 site in 1 country
- The Second Xiangya Hospital of Central South UniversityChangsha, Hunan, China